Hiromichi Ebi

8.5k total citations · 1 hit paper
87 papers, 4.0k citations indexed

About

Hiromichi Ebi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hiromichi Ebi has authored 87 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 45 papers in Molecular Biology and 40 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hiromichi Ebi's work include Colorectal Cancer Treatments and Studies (29 papers), Lung Cancer Treatments and Mutations (27 papers) and Cancer Genomics and Diagnostics (16 papers). Hiromichi Ebi is often cited by papers focused on Colorectal Cancer Treatments and Studies (29 papers), Lung Cancer Treatments and Mutations (27 papers) and Cancer Genomics and Diagnostics (16 papers). Hiromichi Ebi collaborates with scholars based in Japan, United States and China. Hiromichi Ebi's co-authors include Jeffrey A. Engelman, Cyril H. Benes, Seiji Yano, Ryan B. Corcoran, Mari Mino–Kenudson, Patricia Della Pelle, Jeffrey Settleman, Anthony C. Faber, Eugene Lifshits and Kenneth E. Hung and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Hiromichi Ebi

84 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

2012 767 citations Ryan B. Corcoran, Hiromichi Ebi et al. Cancer Discovery profile →

Peers

Hiromichi Ebi

ONCOL

PRM

PFM

Ludmila Prudkin United States

Adrian M. Jubb United Kingdom

Samuel E. DePrimo United States

Susan M. Edgerton United States

Ken A. Olaussen France

A R Bianco Italy

Simona Lamba Italy

Hatim Husain United States

Sandra O’Toole Australia

Youngchul Song United States

Ludmila Prudkin United States

Hiromichi Ebi

1.7k ×0.7

1.9k ×1.0

ONCOL

804 ×0.6

PRM

1.5k ×1.5

537 ×0.8

PFM

Citations per year, relative to Hiromichi Ebi Hiromichi Ebi (= 1×) peers Ludmila Prudkin

Countries citing papers authored by Hiromichi Ebi

Since Specialization

Citations

This map shows the geographic impact of Hiromichi Ebi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiromichi Ebi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiromichi Ebi more than expected).

Fields of papers citing papers by Hiromichi Ebi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiromichi Ebi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiromichi Ebi. The network helps show where Hiromichi Ebi may publish in the future.

Co-authorship network of co-authors of Hiromichi Ebi

This figure shows the co-authorship network connecting the top 25 collaborators of Hiromichi Ebi. A scholar is included among the top collaborators of Hiromichi Ebi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiromichi Ebi. Hiromichi Ebi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kotani, Daisuke, Hideaki Bando, Hiroya Taniguchi, et al.. (2024). Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).. Journal of Clinical Oncology. 42(16_suppl). 3585–3585. 1 indexed citations

Hayashi, Ryuji, Junichi Matsubara, Masahiro Yoshioka, et al.. (2024). Molecularly matched therapies identified by comprehensive genomic profiling before the first-line setting to provide alternative treatment outcomes in patients with solid tumors: 1-year follow-up of the prospective FIRST-Dx study.. Journal of Clinical Oncology. 42(16_suppl). 3137–3137.

Tanaka, Noritaka & Hiromichi Ebi. (2024). Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt. Cancer Science. 116(3). 600–612. 3 indexed citations

Lai, Xianning, Hiu Yan Lam, Yuta Adachi, et al.. (2023). SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition. npj Precision Oncology. 7(1). 136–136. 3 indexed citations

Adachi, Yuta, et al.. (2023). Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Nature Cancer. 4(6). 829–843. 40 indexed citations

Ando, Hitoshi, Kei Irie, Naoya Hashimoto, et al.. (2022). Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. European Journal of Clinical Pharmacology. 78(8). 1239–1247. 5 indexed citations

Matsushita, Masaki, Takaaki Okamoto, Toyofumi F. Chen‐Yoshikawa, et al.. (2022). Meclozine Attenuates the MARK Pathway in Mammalian Chondrocytes and Ameliorates FGF2-Induced Bone Hyperossification in Larval Zebrafish. Frontiers in Cell and Developmental Biology. 9. 694018–694018. 6 indexed citations

Taniguchi, Hiroya, Yoshiaki Nakamura, Daisuke Kotani, et al.. (2021). CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Science. 112(7). 2915–2920. 92 indexed citations

Adachi, Yuta, Kentaro Ito, Yuko Hayashi, et al.. (2020). Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(22). 5962–5973. 146 indexed citations

10.

Yaeger, Rona, Daisuke Kotani, Sebastián Mondaca, et al.. (2019). Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer. Clinical Cancer Research. 25(23). 7089–7097. 85 indexed citations

11.

Kitai, Hidenori, Hiromichi Ebi, Shuta Tomida, et al.. (2016). Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS -Mutant Lung Cancer. Cancer Discovery. 6(7). 754–769. 108 indexed citations

12.

Ebi, Hiromichi, Isao Oze, Takayuki Nakagawa, et al.. (2014). Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations. Journal of Thoracic Oncology. 10(1). 59–66. 11 indexed citations

13.

Nakagawa, Takayuki, Shinji Takeuchi, Tadaaki Yamada, et al.. (2013). EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition. Cancer Research. 73(8). 2428–2434. 136 indexed citations

14.

Ebi, Hiromichi, Carlotta Costa, Anthony C. Faber, et al.. (2013). PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proceedings of the National Academy of Sciences. 110(52). 21124–21129. 174 indexed citations

15.

Corcoran, Ryan B., Hiromichi Ebi, Alexa B. Turke, et al.. (2012). EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. Cancer Discovery. 2(3). 227–235. 767 indexed citations breakdown →

16.

Xu, Lu, Eiki Kikuchi, Chunxiao Xu, et al.. (2012). Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET. Cancer Research. 72(13). 3302–3311. 88 indexed citations

17.

Ebi, Hiromichi, Ryan B. Corcoran, Anurag Singh, et al.. (2011). Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Journal of Clinical Investigation. 121(11). 4311–4321. 153 indexed citations

18.

Ebi, Hiromichi, Shuta Tomida, Toshiyuki Takeuchi, et al.. (2009). Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses. Cancer Research. 69(9). 4027–4035. 31 indexed citations

19.

Minami, Hironobu, Kenji Kawada, Hiromichi Ebi, et al.. (2008). Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Science. 99(7). 1492–1498. 108 indexed citations

20.

Kawada, Kenji, et al.. (2005). Phase I and pharmacokinetic study of weekly docetaxel (DOC) plus irinotecan (IRN) in patients with advanced solid tumors. Cancer Research. 65. 938–938. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact